New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:11 EDTADHDAlcobra completes patient recruitment in Phase III clinical trial of MDX
Alcobra announced that recruitment of patients has been completed in the company's Phase III clinical trial of Metadoxine Extended Release, or MDX, in adult ADHD patients. The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale, or CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA, or Test of Variables of Attention, which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
16:24 EDTADHDAlcobra announces completion of all patient visits in phase 3 MDX trial
Subscribe for More Information
September 12, 2014
11:03 EDTADHDOptions with increasing implied volatility
Options with increasing implied volatility: ADHD VNET AVNO RAX VALE NLY EWZ BBBY SYY GGP
September 10, 2014
11:23 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 9, 2014
12:08 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 8, 2014
10:17 EDTADHDAlcobra October volatility elevated into Phase III trial data
Alcobra September call option implied volatility is at 170, October is a t 289, December is at 203; compared to its 13-week average of 187 according to Track Data, suggesting large October price movement into Phase III trial data of MDX in adult ADHD subjects.
09:33 EDTADHDAlcobra Phase III data could be major stock mover, says FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use